Dr. Daniel Dilling, MD
Claim this profileLoyola University Medical Center
Studies Idiopathic Pulmonary Fibrosis
Studies Fibrosing Alveolitis
14 reported clinical trials
20 drugs studied
Area of expertise
1Idiopathic Pulmonary Fibrosis
rs3570920 TT positive
2Fibrosing Alveolitis
rs3570920 TT positive
CTD-ILD
Affiliated Hospitals
Clinical Trials Daniel Dilling, MD is currently running
Inhaled Treprostinil
for Pulmonary Fibrosis
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Recruiting1 award Phase 311 criteria
Registry
for Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Recruiting1 award N/A8 criteria
More about Daniel Dilling, MD
Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel Dilling, MD has experience with
- Placebo
- Inhaled Treprostinil
- BBT-877
- Molgramostim
- Centralized Lung Evaluation System
- Lung Transplant
Breakdown of trials Daniel Dilling, MD has run
Idiopathic Pulmonary Fibrosis
Fibrosing Alveolitis
Interstitial Lung Disease
Lung Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Dilling, MD specialize in?
Daniel Dilling, MD focuses on Idiopathic Pulmonary Fibrosis and Fibrosing Alveolitis. In particular, much of their work with Idiopathic Pulmonary Fibrosis has involved rs3570920 TT positive patients, or patients who are undergoing treatment.
Is Daniel Dilling, MD currently recruiting for clinical trials?
Yes, Daniel Dilling, MD is currently recruiting for 2 clinical trials in Maywood Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel Dilling, MD has studied deeply?
Yes, Daniel Dilling, MD has studied treatments such as Placebo, Inhaled Treprostinil, BBT-877.
What is the best way to schedule an appointment with Daniel Dilling, MD?
Apply for one of the trials that Daniel Dilling, MD is conducting.
What is the office address of Daniel Dilling, MD?
The office of Daniel Dilling, MD is located at: Loyola University Medical Center, Maywood, Illinois 60153-3328 United States. This is the address for their practice at the Loyola University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.